Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Group 1 - Adverum Biotechnologies is a clinical-stage company focused on gene therapy for prevalent ocular diseases, aiming to establish it as a new standard of care [2] - The company is developing a gene therapy candidate, ixoberogene soroparvovec (Ixo-vec), for a one-time intravitreal injection to treat neovascular or wet age-related macular degeneration [2] - Adverum's proprietary intravitreal platform is designed to provide durable therapies that eliminate the need for frequent ocular injections, thereby transforming the treatment paradigm for ocular diseases [2] Group 2 - Laurent Fischer, M.D., the CEO of Adverum, will participate in a fireside chat at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference on August 15, 2024 [1] - The webcast of the fireside chat will be accessible on Adverum's website, with a replay available for at least 30 days post-presentation [1]